Project description
Next-generation influenza vaccines
The strategic goals of the EU-funded INCENTIVE project are to advance knowledge of the underlying mechanisms of poor responsiveness to influenza vaccines (IVs) and to develop two next-generation universal IVs. This is a partnership between Indian, European and US groups that address the global health and economic challenge posed by influenza infections. The objectives include: performing comprehensive profiling of responders and non-responders to licensed IVs in infants, children, adults and elderly in phase IV trials in Europe and India to identify the mechanisms of vaccine responsiveness; advancing the development of two next-generation vaccines by providing a proof-of-concept for vaccine efficacy in non-human primates for an antigen presenting cell-targeted nucleic acid vaccine and developing a computationally-optimized vaccine up to phase II clinical trials and vaccine efficacy in a controlled human challenge; identifying predictive biomarkers of responsiveness to vaccination for new diagnostics; implementing technology transfer; and performing a health systems and investment analysis.
Field of science
- /natural sciences/biological sciences/biochemistry/biomolecules/nucleic acid
- /medical and health sciences/health sciences/infectious disease/RNA virus/influenza
Programme(s)
Call for proposal
H2020-SC1-2019-Single-Stage-RTD
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
38124 Braunschweig
Germany
Participants (18)
110070 New Delhi
121001 Faridabad
1050 Bruxelles
5020 Bergen
0313 Oslo
2000 Antwerpen
2333 ZA Leiden
75724 Paris Cedex 15
38302 Wolfenbuttel
08036 Barcelona
69007 Lyon
30602-7411 Athens
1901 XX Castricum
1003 Lausanne
19808 Wilmington New Castle
600036 Chennai
400012 Mumbai
110067 New Delhi
